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A MALABSORPTIVE syndrome may occur in association with neoplastic disease
arising in the lymphoreticular system with involvement ofthe small bowel (Baker
and Mann, 1939; Sleisenger, Almy and Barr, 1953; Gough, Read and Naish, 1962;
Kent, 1964).
Creamer (1964), Hindle and Creamer (1965) and Dymock (1966) have reported
small intestinal mucosal abnormalities in patients with malignant disease.
Impaired D-xylose absorption in similar patients has been reported previously
(Dymock, 1965). Disordered folic acid metabolism in non-intestinal malignant
disease has been demonstrated by Karlin (1963), Rama Rao et al. (1963), Kershaw
and Girdwood (1964), Dymock (1964a), and Rose (1966) and may contribute to
the anaemia of malignancy.
In view of these findings a prospective study of small bowel function and
anaemia has been carried out in twenty-six patients suffering from neoplastic
disease.
MATERIALS AND METHODS
Twenty-six patients with malignant disease were studied; the sites of the
primary growth are listed in Table I. The group consisted of sixteen male and
TABLE I.-Sites ofPrimary Neoplasm
Bronchus . . . . 10
Stomach . . . . 6
Reticuloendothelial system . 3
Prostate . . . 2
Colon . . . . 1
Brain . . . . 1
Kidney. 1
Breast . . . . 1
Myelofibrosis. . . 1
ten female patients ranging in age from 32 to 80 years. Before this study, three
patients (t in Table II) had been treated with cytotoxic drugs and one patient
(No. 16) had received abdominal radiotherapy.
Full peripheral blood examinations were carried out using standard laboratory
techniques (Dacie and Lewis, 1963). Sternal marrow studies were made in
eleven patients.
* Present address: Gastro-Intestinal Unit, Western General Hospital, Edinburgh 4.
22506 DYMOCK, MACKAY, MILLER, THOMSON, GRAY, KENNEDY AND ADAMS
TABLE II.-Haematological Result8 in Twenty-8iX Patient8 with Neoplk8ia
Diagnosis
Carcinoma ofbronchus
Carcinoma ofbronchus
Carcinoma ofbronchus
Carcinoma of prostate
Carcinoma of bronchus
Carcinoma of stomach
Carcinoma of bronchus
Carcinoma of colon
Astrocytoma
Carcinoma of stomach
Carcinoma of bronchus
Carcinoma of bronchus
Carcinoma of bronchus
Carcinoma of prostate
Carcinoma of stomach
Carcinoma ofkidney
Carcinoma of breast
Lymphadenoma
Carcinoma of bronchus
Carcinoma ofstomach
Carcinoma of stomach
Carcinoma ofstomach
Myelofibrosis
Reticulum cell sarcoma
Lymphadenoma
Carcinoma of bronchus
Haemoglobin
g. per 100 ml.
13*7
14*7
12*0
12*0
8*6
12-2
13-6
13*0
14*3
11*8
13-6
11*6
15*2
12*8
13*2
11*8
16*0
13-7
12*7
11*6
12*3
13*8
854
13*0
10'0
12-2
Blood film
Normochromic
Normochromic
Normochromic
Anisocytosis/poikilocytosis
Hypochromia
Normochromic
Normochromic
Normochromic
Normochromic
Anisocytosis/poikilocytosis
Normochromic
Normochromic
Normochromic
Normochromic
Normochromic
Normochromic
Normochromic
Normochromic
Normochromic
Hypochromia
Hypochromia
Leukoerythroblastosis
Normochromic
Normochromic
Normochromic
Marrow examination
Normoblastic
Normoblastic/hyperplastic
Normoblastic
Normoblastic
Normoblastic/hypoplastic
Normoblastic/hyperplastic
Normoblastic
Normoblastic/hyperplastic
Normoblastic
Normoblastic
Dry tap
Normoblastic
Normoblastic
Bromsulphthalein retention was measured 45 minutes after the intravenous
administration of a 5 mg. per kg. body weight dose (King and Wootton, 1956).
Stool fat excretion was measured as stearic acid by the method of van de
Kamer et al. (1949), and expressed as the average 24-hour output over a minimal
3-day period. A normal ward diet was continued during the period studied.
The urinary D-xylose excretion was measured in the 5-hour period following a
5 g. oral dose by the method of Santini, Sheehy and Martinez de Jesus (1961).
(Normal range 1-2-2-4 g.)
The serum iron level and total iron binding capacity were measured by the
method of Ramsay (1958).
Urinary formiminoglutamic acid (FIGLU) and urocanic acid (U.A.) were
determined in the 8 hours following the oral administration of 15 g. l-histidine
by the enzymatic method of Chanarin and Bennett (1962). The normal range
for this laboratory is 0-25 mg.
The level ofVitamin B12 in the serum was assayed by the method ofHutner,
Bach and Ross (1956) using Euglena gracili8 as the test organism. Vitamin B12
absorption was assessed following the oral administration of 0 5 ,ug. Vitamin B12
labelled with 05 /LC 58Co. The 24-hour urinary excretion was expressed as a
percentage of the oral dose (Schilling, 1953). In three subjects the test was
repeated after one week with the addition of Intrinsic Factor (Lederle).
Nine jejunal biopsies were obtained in eight patients; in two the specimen was
obtained at laparotomy and in the other seven by the peroral route using the
Watson biopsy capsule. In the latter instances radiological examination con-
firmed the presence of the capsule in the jejunum before the biopsy was taken.
The histological appearances were assessed by one of us (B.G.). The criteria
used were those employed by Salem and Truelove (1965).
Patient
number
1
2
3
4
5
6.
7.
8.
9.
10
11
12
13
14
15
16
17
181
19
20
21
22
23
24t.
25t
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RESULTS
The results are tabulated in Tables II and III.
TABLE III.-Results ofIntestinal and Hepatic Function Tests
B.S.P. Xylose Stool Histidine Serum Schilling
retention excretion fats metabolites B12 test
Patient at 45 min. g./5 hr. g./day mg./8hr. spg./ml. % excretion
1 . 6 . 3 0 . . 194 . 95 . 3.5
2 . 5 1.9 10*6 . 47 . 239 . 7-1
3 . 4 . 11 . 04 . 252 . 450 . 99
4 . 23 . . . 63 . 203
5 . 5 . 02 10*2 . 96 . 377 . 3.1
6 . 30 . 0.4 . 7*6 . 33 . 316 4.7
7 . 5 . 14 3-2 8 . 620 . 15-9
8 . 21 . 1.0 . 78 . 457
9 . 3 . 1-5 . . 18 . 265 17*6
10 . 18 . 0 63 . . 3 . 352 . -
11 . 5 . 1*4 . 8-5 . 4 . 900 . 0
12 . 4 . 2.5 . 4-8 . 84 . 123
13 . 7 . 25 . 7.25 . 33 . 418 . 7
14 . 16 . 1.5 . 26 . 173 . 15
15 . - . 11 . . 4 . 133 . 11.5
16 . 9 . 04 . . 150 . 259 . 15
17 2 . 1*7 . . 16 . 312
18 . . 0.76 . . 81 . 304 . 11-7
19 . 0 . 1*3 . - - . 241
20 . 10 . 1-8 3 . 35 363 . 10.1
21 . 0 . 0*2 . 11 . 389
22 - . .
23 4 . 03 . 1-2 . 167 . - . 8-f
24 . 6 . 0-6 . 6-0 . 77 . 399
25 . 7 . 019 3 9 . 208 . 175 . 0
26 . 36 . 1-4 . 3-1 . 55 . 317
A haemoglobin estimation was carried out in all patients. Nine ofthe twenty-
six patients had haemoglobin levels of 12-0g. per 100 ml. or less but in only two
patients was there severe anaemia; patient 5 who had a bronchogenic carcinoma
had a level of 8-6 g. per 100 ml. and patient 23 with myelofibrosis had 8 4 g. per
100 ml. The blood film was normal in four of these nine patients; two showed
hypochromia; two showed anisocytosis and poikilocytosis; the patient with
myelofibrosis had a leukoerythroblastic blood picture; none exhibited macro-
cytosis. All the other patients had a normal peripheral blood film.
Sternal marrow examination was carried out in eleven patients. All showed
normoblastic erythropoiesis. In none of the patients with carcinoma was there
evidence of tumour infiltration of the marrow, or of early megaloblastic change.
Three patients had hyperplastic marrow tissue and in one there was apparent
hypoplasia.
Serum iron levels and total iron binding capacity (T.I.B.C.) were determined
in twenty-five patients. The range for the serum iron level was 13-183,ug.
per 100 ml. and the T.I.B.C. varied between 165 and 396,ug. per 100 ml. In
twelve patients the serum iron level was less than 50,ug. per 100 ml. but in none
was there an associated increase in the T.I.B.C. No patient showedthe character-
istic serum changes ofiron deficiency (a low serum iron with a raised T.I.B.C.) and
the two patients with hypochromic blood films had normal serum levels.
Vitamin B12 absorption was measured by means of the Schilling test in
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occurred in five patients and between 5 % and 10 % in a further four. In three
patients with a low urinary excretion (all less than 5 %) the test was repeated with
the addition ofIntrinsic Factor but in none was there any significant augmentation
of the absorption. In only two patients was there marginal reduction of the
serum vitamin B12 level (123 and 133 ,u,ug. per ml.).
Urinary FIGLU and urocanic acid was estimated in twenty-four patients.
Abnormal results (more than 25 mg. in 8 hours) ranging from 26 to 252 mg. were
obtained in seventeen patients.
Xylose excretion was measured in twenty-four patients. Abnormal results
(less than 1*2 g. in 5 hours) were found in twelve patients. Only two of these
patients had lesions involving the urinary tract and in neither was the blood urea
elevated. The three patients who had received cytotoxic drugs and the patient
who had been treated with radiotherapy all had abnormal xylose excretion.
The stool fat excretion was studied in thirteen patients. In five instances the
average daily excretion exceeded 6-0 g. (range 7-25-10-6 g. per 24 hours).
Bromsulphthalein retention exceeded 10 per cent at 45 minutes in seven of
twenty-three patients studied (Table IV). Xylose results were available for
TABLE IV.-Correlation ofB.S.P. Retention and Xylose Excretion
Normal Abnormal
B.S.P. B.S.P.
retention retention
Normal Xylose excretion . 10 . 3
Abnormal Xylose excretion . 6 . 3
comparison in twenty-two of these patients. In ten patients normal results were
found in both tests and in three both were abnormal but in a further nine patients
there was no correlation. The finding of abnormal D-xylose excretion in six
patients with a normal B.S.P. retention test would appear to exclude hepatic
dysfunction as a cause of the malabsorption in at least a proportion of cases.
Of ten patients in whom the xylose test, stool fat excretion and Schilling test
were performed, histidine metabolite excretion was abnormal in eight. Only one
of these eight patients showed no abnormality in the other function tests. The
two patients with normal histidine metabolite excretion gave normal results with
the other tests and both had normal haemoglobin levels. There would appear
to be a close connection between the excretion of abnormal quantities of histidine
metabolites and the disordered intestinal function. Both patients with severe
anaemia showed evidence of small intestinal malfunction.
In the present study when using the Schilling test, xylose, stool fat and
histidine metabolite excretions as parameters of small intestinal function, in only
five cases were all four tests normal and in eight other patients only one of these
tests gave an abnormal result. Five patients had abnormalities ofthree tests and
two gave abnormal results in all four. The remaining six patients had abnormali-
ties in only two tests. It was not possible to carry out all four tests in every
subject and these figures probably represent an underestimate of the incidence of
abnormalities. In total seventy-seven tests were carried out and of these forty-
three gave abnormal results.
The results of jejunal mucosal biopsies are shown in Table V. In seven
patients the appearances on histological examination were those of a partial
villous atrophy and in one patient sub-total atrophy was present. One patientSMALL INTESTINAL FUNCTION IN NEOPLASTIC DISEASE
who had myelofibrosis had biopsies carried out on two occasions with an interval
often months between them. In both instances the appearances were abnormal.
TABLE V.-Comparison of Biopsy Findings and Tests of Intestinal Function
Patient Jejunal D-Xylose Stool fat Schilling Histidine
number Diagnosis biopsy absorption excretion test metabolites
5 Carcinoma of . partial villous + + + +
bronchus atrophy
7 . Carcinoma of . partial villous . 0 . 0 . 0 . 0
bronchus atrophy
11 Carcinoma of . subtotal villous . 0 + 0 . +
bronchus atrophy
14 . Carcinoma of . partial villous 0 .. 0 . +
prostate atrophy
21 . Carcinoma of . partial villous + .. 0
stomach atrophy
22 . Carcinoma of . partial villous .. . ..
stomach atrophy
23 . Myelofibrosis . partial villous + 0 + +
atrophy
25 . Hodgkin's . partial villous . + 0 . + +
disease atrophy
DISCUSSION
The occurrence of a malabsorption syndrome in association with neoplastic
disease involving the gastro-intestinal tract is well recognised. The primary
lesion in these patients had been one of the reticuloses and the literature on this
subject has recently been reviewed by Kent (1964) and Eakins, Fulton and Hadden
(1964). It was formerly believed that lymphatic infiltration was the cause of the
malabsorption but it is now appreciated that the syndrome may develop in the
absence of local lymphatic involvement.
Our results show abnormal function of the small intestine in patients with
malignant disease. In seven of our twenty-six patients the primary lesion arose
in the gastro-intestinal tract but there was no preponderance of abnormal results
in these patients.
Definitive tests of absorptive capacity were abnormal in a high percentage of
cases in the present series: xylose excretion was abnormal in twelve out oftwenty-
four, and fat excretion increased above 6 g. in 24 hours in five of the thirteen
patients tested. The Schilling test was abnormal in nine of sixteen patients thus
suggesting that both the jejunum (xylose and fat) and ileum (Schilling test) were
involved.
Abnormal FIGLU excretion in malignant disease has previously been reported
by Dymock (1964a) and Rose (1966). In the present study histidine metabolite
excretion was abnormal in seventeen out of twenty-four patients assessed.
Knowles (1962) and Rose (1965) have found the presence of normal histidine
metabolism to be uncommon in intestinal malabsorption. Dymock (1965) has
shown a possible correlation between abnormalities ofxylose and FIGLU excretion
in malignant disease.
In view ofthese reports and the occurrence ofother abnormalities ofintestinal
function in the present series it would appear that the raised FIGLU excretion
could be attributed to disordered folic acid metabolism due to defective folic acid
absorption as the result of impaired small intestinal function.
The jejunal mucosal changes are of great interest. Unfortunately biopsy
specimens were available from only eight patients in the series but abnormal
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histology was found in all of these (see above). Creamer (1964) reported abnor-
malities ofthe jejunal and ileal mucosa in six out ofnine patients with malignant
disease. Intwo ofCreamer's patients theprimarylesionwaswithinthealimentary
tract but the other four abnormal biopsies were obtained from patients whose
tumour arose in bronchus, adrenal, ovary or cervix. Stool fat results were
available from seven patients inhis series and excessive excretion wasfoundinfive.
Further work (Hindle and Creamer, 1965; Dymock, 1966) has confirmed the
biopsy changes. Our results lend support to those ofCreamer and suggest further
abnormalities. It would appear from both studies that the site of the primary
lesion does not predetermine the development of abnormal small intestinal
function.
The question arises as to whether these changes are specific to malignant
disease or are simply a manifestation ofa chronic disease process. Abnormalities
of small intestinal structure and function may occur in association with other
diseases.
Salem and Truelove (1965) found abnormal villous structure in forty-one of
sixty patients suffering from ulcerative colitis. Abnormal faecal fat excretion and
D-xylose excretion were also recorded by the same authors who suggested that
the changes may be ofa temporary nature related to the stage ofthe disease.
Schwarz (1964) found steatorrhoea in patients with cirrhosis of the liver and
showed that the malabsorption offat wasnot due to lack ofbile salts in the small
intestine: he suggested that this dysfunction might result from pathological
changes in the small bowel secondary to portal hyperaemia. In none of the
patients described was hepatic cirrhosis present; the bromsulphthalein retention
test was normal in sixteen of twenty-three patients in this series. Jaundice was
not a feature of any of these patients. It has also been shown that abnormal
folate metabolism in malignant disease mayoccurinthe presence ofnormalhepatic
function (Dymock, 1964b).
Disordered folic acid metabolism and small bowel dysfunction may occur in
association with skin diseases. Watson, Paton and Murray (1965) found jejunal
mucosal abnormalities in twenty of sixty patients with acne rosacea whom they
studied. Shuster and his colleagues (Shuster and Marks, 1965; Knowles, Shuster
and Wells, 1963; Fry, Shuster and McMinn, 1965) havealsoshownabnormalitiesof
D-xylose excretion, stool fat excretion, and urinary FIGLU output in a variety of
skin diseases.
Evidence ofdisordered small bowel histology and/or function has beenreported
in sarcoidosis (Hindle and Creamer, 1965), diabetes mellitus (Vinnik, Kern and
Struthers, 1962), viral hepatitis (Sheehy, Artenstein and Green, 1964) and tuber-
culosis (Hindle and Creamer, 1965).
There would appear to be little doubt that malignancy can be associated with
abnormal intestinal structure and function. In view of the reports of jejunal
abnormalities in association with other clinical conditions it is unlikely that the
intestinal features are specific to malignant disease but the precise mechanism of
their production awaits elucidation. The possible contribution of the disordered
intestinal function to the cachexia ofmalignancy merits consideration.
SUMMARY
Small intestinal function has been assessed in twenty-six patients suffering
frommalignantdisease. Usingthe xylose absorption, stool fatexcretion, histidineSMALL INTESTINAL FUNCTION IN NEOPLASTIC DISEASE 511
metabolite excretion and the Schilling test, abnormal results were obtained in a
high percentage ofpatients. Abnormal jejunal structure was demonstrated in all
eight patients inwhom mucosal biopsywas carried out. The implications ofthose
abnormalities are considered in relation to the reports of defective intestinal
structure and function in other chronic diseases. Impaired small intestinal
function of a non-specific type may occur in malignant disease processes arising
outwith the alimentary tract.
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